Skip to content

Main Navigation

Clinical Study

Compare the Study Drug Remibrutinib to an approved drug Teriflunomide for People with Relapsing Multiple Sclerosis (RMS)

MS is a long-lasting disease that can affect a persons brain and spinal cord. Teriflunomide is an approved drug to reduce relapsing MS (RMS). Remibrutinib is a study drug to reduce RMS. Research is needed to learn the safety and effectiveness of the study drug. While also seeing if it reduces RMS better than Teriflunomide. The information we learn will aid future patients.

I AM INTERESTED

For more information contact:

Trieste Francis

  trieste.francis@hsc.utah.edu
  801-587-3864

IRB#: IRB_00152490 | PI: M. Mateo Paz Soldan | Department: NEUROLOGY | Approval Date: 2022-05-25 06:00:00
Study Categories: Brain Health Studies | Specialties: Neurology

Who can participate?

 Gender: All

 Age: Over 18 years old

 Volunteers: Volunteers with special conditions

 Location: In Person


Inclusion Criteria:

  • Ages 18-55
  • RMS diagnosis
  • At least 1 relapse within the past year
  • Positive mental health 1 month before participating
  • Attend in-person at the University of Utah

Exclusion Criteria:

  • Progressive MS diagnosis
  • RMS more than 10 years
  • History of other specific diseases such as stroke, brain or spinal injury
  • Current drug or alcohol abuse
  • Pregnant

Will I be paid for my time?

Yes

Last Updated: 4/5/21